Why it matters: management review turns operational data into strategic decisions before regulators spot weaknesses.
Management review proves the quality leadership is actively steering the system, not just reacting to audit findings.
Management review expectations appear across GMP standards:
Regulatory callout: regulators expect documented meeting minutes that tie risk trends, CAPA, and resource changes to decisions.
Inspectors typically ask first if management review actually happens:
Inspector insight: missing or superficial minutes quickly become evidence of ineffective oversight.
Weak management review records mean leadership isn’t in control:
Failure callout: if management review minutes feel like paperwork, inspectors treat the whole system as window dressing.
A modern eQMS keeps management review documented and defensible:
Complere gives leadership visibility into the quality story so reviews deliver improvement, not just compliance.
Complere brings QA metrics, CAPA, deviations, training, and audit trails into one dashboard so leadership can see decisions in context.
Inspectors review agendas, actions, ownership, risk assessments, CAPA trends, audit findings, and evidence that leadership acted on quality data.
Management review is the senior leadership assessment of quality metrics, CAPA status, audit findings, and resource needs to ensure the pharmaceutical quality system remains effective.
FDA 21 CFR 211.22, EU GMP Chapter 1, PIC/S, and ICH Q10 expect documented periodic management reviews.
Daily metrics report performance; management review adds governance by evaluating trends, risks, CAPA effectiveness, and making strategic decisions.
Complere helps regulated teams prepare management review with more connected quality data, clearer exports, and a stronger evidence trail behind leadership decisions.
Audit ready | Better review inputs | Stronger governance visibility